Enoxaparin + Apixaban + BAY1213790

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Knee Arthroplasty, Total

Conditions

Knee Arthroplasty, Total

Trial Timeline

Sep 21, 2017 → Jan 2, 2019

NCT ID

NCT03276143

About Enoxaparin + Apixaban + BAY1213790

Enoxaparin + Apixaban + BAY1213790 is a phase 2 stage product being developed by Bayer for Knee Arthroplasty, Total. The current trial status is completed. This product is registered under clinical trial identifier NCT03276143. Target conditions include Knee Arthroplasty, Total.

What happened to similar drugs?

11 of 20 similar drugs in Knee Arthroplasty, Total were approved

Approved (11) Terminated (0) Active (9)

✅NISEDr. Reddy's LaboratoriesApproved

✅Capsaicin Topical SolutionAstellas PharmaApproved

✅ImrecoxibJiangsu Hengrui MedicineApproved

✅celecoxibPfizerApproved

✅Ibuprofen + Placebo + CelecoxibPfizerApproved

✅Celecoxib + Naproxen + PlaceboPfizerApproved

✅Celecoxib + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03276143	Phase 2	Completed	Sep 21, 2017	Jan 2, 2019	Knee Arthroplasty, Total

Competing Products

20 competing products in Knee Arthroplasty, Total

See all competitors

Product	Company	Stage	Hype Score
NISE	Dr. Reddy's Laboratories	Approved	40
NISELAT	Dr. Reddy's Laboratories	Pre-clinical	23
LY2828360 + Placebo	Eli Lilly	Phase 2	35
UBX0101 or placebo	Unity Biotechnology	Pre-clinical	8
UBX0101	Unity Biotechnology	Phase 1	19
UBX0101	Unity Biotechnology	Phase 2	25
UBX0101	Unity Biotechnology	Phase 1	19
YH23537 + Celecoxib + YH23537 placebo	Yuhan	Phase 2	35
YM150 + Warfarin	Astellas Pharma	Phase 2	35
ASP7962 + Naproxen + Placebo	Astellas Pharma	Phase 2	35
Capsaicin Topical Solution	Astellas Pharma	Approved	43
CGS-200-1 + CGS-200-5 + CGS-200 Vehicle	Astellas Pharma	Phase 2	35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo	Sun Pharmaceutical	Phase 2	35
Duloxetine + Placebo	Shionogi	Phase 3	40
Duloxetine	Shionogi	Phase 3	40
V120083 + Naproxen + Placebo	Shionogi	Phase 2	35
ONO-4474 + Placebo matching ONO-4474	Ono Pharmaceutical	Phase 2	27
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine (DLX) + Placebo (PLA)	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40